Loading
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Latest quote
$2.50
−$0.07 · -2.72%
After-hours
$2.40
−$0.10 · -4.00%
Sep 10, 6:34 PM ET
Regular session · ET · Market data may be delayed.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Day range
Current $2.50
52-week range
Current $2.50
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
12
Overpriced
Sentiment
54
Mixed
Risk
66
High Risk
Momentum
36
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Day range
Current $2.50
52-week range
Current $2.50
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 56K USD | 3.15M USD | 500K USD | 3.46M USD |
| Cost of goods sold | — | 194K USD | 90K USD | — | 3.8M USD |
| Gross profit | — | −138K USD | 3.06M USD | 500K USD | −333.84K USD |
| Research and development | 13.16M USD | 7.48M USD | 2.39M USD | 1.57M USD | 3.8M USD |
| Selling, general, and administrative | 11M USD | 9.43M USD | 3.89M USD | 1.29M USD | 1.3M USD |
| Operating expenses | 24.02M USD | 16.91M USD | 6.19M USD | 2.77M USD | 1.3M USD |
| Interest income | — | — | — | 1.76K USD | 10.86K USD |
| Interest expense | 213K USD | 526K USD | 558K USD | 15.88K USD | 3.09K USD |
| Depreciation and amortization | 73K USD | 194K USD | 90K USD | 61.27K USD | 33.37K USD |
| Operating income | −24.02M USD | −17.05M USD | −3.13M USD | −2.27M USD | −1.63M USD |
| Net income | −19.18M USD | −11.14M USD | 5.27M USD | −2.68M USD | −1.26M USD |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
